Cloudbreak Pharma’s Global Innovative Ophthalmic Pipeline CBT-001 Completes the Enrollment of All Patients in the International Multi-Center Phase III Clinical Trial

Cloudbreak Pharma Inc. is pleased to announce that our pipeline CBT-001, the global innovative ophthalmic drug for the treatment of pterygium has recently completed the enrollment of all patients in global centers in its international multicenter Phase III clinical trial. This study is a randomized, double-blind, placebo-controlled Phase III clinical trial, planning to enroll 660 […]

Cloudbreak Pharma Inc.’s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States

Cloudbreak Pharma Inc.’s CBT-004 indicated for the treatment of vascularised pinguecula has completed Phase II clinical trials in the United States Cloudbreak Pharma Inc. has completed the Phase II clinical trial investigating CBT-004 for the treatment of vascularized pinguecula in the United States in April. Preliminary results demonstrated excellent ocular and systemic safety profile. The […]

CBT-004 has completed the first patient-in for Phase 2 clinical trials in the US

We are proud to announce that CBT-004, a potential first-in-class drug for vascularised pinguecula, has completed the first patient-in for Phase 2 clinical trials in December 2023 in the US. Pinguecula is a round, yellowish, elevated tissue that develops on the conjunctiva adjacent to the cornea. Cumulative exposure to UV light is the main cause […]

Remarkable Progress in Clinical Trials: CBT-009 and CBT-004

We are proud to announce that  CBT-009, our novel ophthalmic formulation of atropine indicated for the treatment of juvenile myopia, has reached agreement with FDA to enter into Phase 3 clinical trial in the USA. We have submitted our application to FDA for conducting a Phase 2 clinical trial in the United States to test […]

Seeing Life Better Through Medicine

Imagine a world where everyone can experience the joy and beauty of clear vision. At Cloudbreak, our mission is centered around the belief that vision is not just a sense but a gateway to a more fulfilling life. We strive to empower individuals by improving their vision and reducing the burden of eye disease. Through […]

Cloudbreak: A Clinical-Stage Company Dedicated to Improving Vision Health

Perhaps you are unfamiliar with us and unsure of what motivates us to become a mission-driven company. Today, we are excited to share our story with you. Cloudbreak is a clinical-stage biotechnology company on a mission to improve the vision quality of people worldwide. We aim to help them see life better through medicine by […]

Cloudbreak Pharma Named a Potential Unicorn for 2023

  On June 20th, 2023, Greatwall Strategy Consultants (GEI) released the “2023 China Potential Unicorns Research Report”. Cloudbreak Pharma is honoured to be named one of the potential unicorn companies in China. The report showed that Suzhou ranked third in the country and first in the province in terms of number of potential unicorns with […]

Cloudbreak Pharma Inc. and Centre for Eye and Vision Research Ltd. sign a memorandum of understanding for strategic cooperation in Hong Kong

On May 17th, Cloudbreak Pharma Inc. (Cloudbreak) and Centre for Eye and Vision Research Ltd. (CEVR) signed a memorandum of understanding for strategic cooperation at the Asia Summit on Global Health (ASGH) in Hong Kong. The parties intend to explore opportunities to collaborate on research in ocular science and have reached a preliminary understanding of […]

Abu Abraham, M.D.’s appointment as Chief Medical Officer

We are pleased to announce that Abu Abraham, M.D. has joined as the group’s Chief Medical Officer.     Dr. Abu Abraham has over 20 years of working experience in the pharmaceuticals and medical area.  He formerly served as Vice President and Global Head of Retina and Vitreous Therapeutics at Santen, where he managed a […]